Philippine formulary medicines with clinical-trial evidence for a new indication
23 of the 348 medicines with a PhTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (5 at L1, 18 at L2), meaning clinical-trial evidence (randomized trials, Phase 2–3 trials or systematic reviews) was found for it.
The medicines come from the Philippine National Formulary Essential Medicines List, 8th Edition (2022) (a national formulary, not a registration database: FDA Philippines registration status is not included); the list reflects the drug reports as last updated on 2026-11-20.
Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.
Medicines with trial evidence (L1–L2)
| Drug | Predicted new indication | Evidence level | Registered trials cited (NCT) |
|---|---|---|---|
| Acetylcysteine | thrombotic disease | L1 | 7 |
| Dapsone | pneumocystosis | L1 | 9 |
| Ketamine | Headache disorder | L1 (with caveat) | 9 |
| Ketorolac | headache disorder | L1 | 10 |
| Nepafenac | Eye disease | L1 | 10 |
| Atorvastatin | HIV infectious disease | L2 | 10 |
| Clozapine | Manic bipolar affective disorder | L2 | 1 |
| Diazepam | Insomnia (disease) | L2 | 0 |
| Docetaxel | Ewing sarcoma | L2 | 8 |
| Doxorubicin | Ewing sarcoma | L2 | 10 |
| Everolimus | Liposarcoma | L2 | 1 |
| Hydrocortisone | Alopecia areata | L2 | 1 |
| Levonorgestrel | Acne (disease) | L2 | 0 |
| Mefenamic Acid | Headache disorder | L2 | 0 |
| Mycophenolate Mofetil | HIV infectious disease | L2 (with caveat) | 4 |
| Oxaliplatin | Malignant pleural mesothelioma | L2 | 3 |
| Potassium | Hypertensive disorder | L2 | 8 |
| Prednisolone | Alopecia areata | L2 | 0 |
| Prednisone | Alopecia areata | L2 | 0 |
| Propofol | Migraine disorder | L2 | 3 |
| Ribavirin | Chronic hepatitis B virus infection | L2 | 8 |
| Sucralfate | Duodenogastric reflux | L2 (with caveat) | 0 |
| Tacrolimus | Seborrheic dermatitis | L2 | 2 |
How to read this list
- Evidence level follows the site’s criteria: L1 = Multiple Phase 3 RCTs / systematic reviews; L2 = Single RCT or multiple Phase 2 trials. “(with caveat)” means the drug report qualifies the grade; read the note in the report before relying on it.
- Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, but some predictions may still overlap an established use; the report explains this where it applies.
- Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
- For all levels and the full method, see High Evidence (L1-L2), Drugs and the methodology.
Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)